GLP-1 drugs continue to dominate the pharmaceutical landscape. The medication is popular for its weight loss applications, and major pharmaceutical companies continue to introduce new versions of ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
The U.S. government awarded Shionogi Inc. a contract worth up to $482 million to expand domestic manufacturing of Fetroja ...
Financially, the agreement includes a $20 million upfront payment to C4 Therapeutics, with the potential for additional ...
VESALIUS-CV data supported evolocumab reducing MACE in high-risk primary prevention diabetes over 4.8 years, reinforcing the ...
Pharmaceutical Executive: How does the complexity of obesity impact the effectiveness of GLP-1s? Mark Bagnall: This is one of ...
In today's Pharmaceutical Executive Daily, activist investor Shah Capital escalates its campaign against Novavax's board ...
Air route diversions and constrained regional access are eroding schedule certainty for temperature-controlled air freight, ...
Shah Capital plans “against” votes on directors and say-on-pay, while seeking to sway ISS and Glass Lewis rather than running ...
The most immediate impacts of the U.S.- Iran conflict is being observed in the supply of active pharmaceutical ingredients ...
Companion diagnostics (CDx), positioned at the intersection of pathology, drug development, and patient access, have emerged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results